Table 1.
Characteristics of vaccinated patients (2002–2009)
| Patient code | Gender | Age (years) | AJCC stage | Primary tumor localization | Metastasis | Additional treatment | DTH | Clinical status | Overall survival (months) |
|---|---|---|---|---|---|---|---|---|---|
| MT015 | M | 30 | IV | Right ventral abdomen | M1a | RT + IL2 | + | Deceased | 40.0 |
| MT018 | F | 63 | IV | Left ankle exterior side | M1b | None | + | Deceased | 36.0 |
| MT019 | M | 19 | IV | Right eye | M1c | Local RT | − | Deceased | 5.0 |
| MT020 | F | 51 | IV | Right uveal tumor | M1c | Local RT | + | Deceased | 41.0 |
| MT021 | F | 61 | IV | Scalp | M1a | None | + | Stable | 80.0 |
| MT023 | M | 40 | IV | Right Malar | M1a | Surgery + RT + IL-2 | − | Deceased | 11.0 |
| MT026 | M | 54 | IV | Ventral left thigh | M1a | Surgery + IL-2 | + | Stable | 78.0 |
| MT027 | M | 47 | IV | Supraumbilical right side | M1b | Surgery | + | Stable | 78.0 |
| MT028 | F | 70 | IV | Vulva | M1b | None | + | Deceased | 7.0 |
| MT029 | M | 42 | IV | Periumbilical | M1b | None | + | Deceased | 16.0 |
| MT030 | F | 81 | IV | Ventral left knee | M1c | Local RT | + | Deceased | 28.0 |
| MT031 | F | 42 | IV | Right eyelid, local extension | M1a | Local RT | − | Deceased | 62.0 |
| MT034 | F | 71 | IV | Subungueal big toe right foot | M1b | None | − | Deceased | 15.0 |
| MT035 | F | 66 | IV | Left dorsal calf | M1a | Surgery + IFN-a | − | Stable | 71.0 |
| MT037 | M | 55 | IV | Right anterior cervical region | M1a | Surgery | − | Deceased | 6.0 |
| MT038 | F | 48 | IV | Right dorsal subscapular hemithorax | M1c | None | + | Deceased | 20.0 |
| MT039 | F | 42 | IV | Ventral right foot | M1a | None | − | Deceased | 13.0 |
| MT040 | M | 59 | IV | Left dorsal thoracic | M1c | Local RT | − | Deceased | 7.0 |
| MT042 | M | 52 | IV | Right inguinal region | M1c | RT + temodal | − | Deceased | 6.0 |
| MT043 | F | 71 | IV | Right heel | M1a | Surgery + DTIC | + | Deceased | 20.3 |
| MT044 | F | 25 | IV | Left scapula | M1a | Local RT | + | Deceased | 8.0 |
| MT045 | M | 19 | IV | ND | M1a | Local RT | + | Progressor | 33.5 |
| MT046 | M | 69 | IV | Back | M1b | None | − | Deceased | 6.0 |
| MT048 | F | 44 | IV | Left forearm | M1c | None | + | Deceased | 9.4 |
| MT049 | M | 54 | IV | Back | M1a | None | + | Stable | 27.0 |
| MT050 | F | 52 | IV | Left foot sole | M1c | RT + temodal | + | Deceased | 3.0 |
| MT053 | F | 72 | IV | Left ankle | M1c | None | − | Deceased | 3.3 |
| MT055 | F | 36 | IV | Left hand | M1c | None | − | Deceased | 9.3 |
| MT058 | F | 52 | IV | Left ankle | M1a | RT | + | Progressor | 27.4 |
| MT060 | M | 42 | IV | Right leg | M1a | IL-2 + RT | + | Progressor | 22.9 |
| MT061 | M | 67 | IV | Urethral meatus | M1c | CTX | − | Deceased | 10.7 |
| MT062 | F | 47 | IV | Dorsal | M1a | CTX | + | Stable | 23.6 |
| MT064 | F | 45 | IV | Pharynx | M1c | CTX | − | Deceased | 15.1 |
| MT065 | F | 40 | IV | Scalp | M1c | CTX | − | Deceased | 5.7 |
| MT066 | M | 54 | IIIC | Abdominal wall | ND | RT + DTIC | + | Stable | 23.1 |
| MT072 | M | 42 | IV | Dorsal | M1c | None | − | Deceased | 10.6 |
| MT076 | F | 29 | IV | Left foot | M1b | RT | + | Stable | 19.2 |
| MT079 | F | 64 | IV | Left flank | M1c | None | − | Deceased | 9.0 |
| MT080 | M | 74 | IV | Palate | M1c | ND | + | Stable | 18.3 |
| MT083 | M | 57 | IIIC | Right hand | N3 | None | − | Progressor | 16.5 |
| MT084 | M | 47 | IIIC | Right hand | N3 | None | + | Stable | 16.3 |
| MT088 | F | 70 | IV | Uveal melanoma | M1c | RT + TAM + DTIC | + | Deceased | 7.4 |
| MT091 | M | 70 | IV | Scalp | M1c | None | + | Stable | 15.5 |
| MT094 | F | 48 | IV | Uveal melanoma | M1c | RT | + | Stable | 14.9 |
| MT096 | M | 46 | IIIA | Dorsal | N2a | None | + | Stable | 14.4 |
| MT101 | M | 41 | IV | Right leg | M1a | None | + | Stable | 13.8 |
| MT102 | F | 46 | IV | Right thigh | M1b | DTIC + Ipimilumab | + | Stable | 14.0 |
| MT103 | F | 47 | IIIB | Left foot | N2b | None | + | Stable | 13.7 |
| MT105 | F | 56 | IIIA | Right left | N2a | None | − | Stable | 13.5 |
| MT112 | M | 67 | IIIA | Dorsal | N2a | None | + | Stable | 11.9 |
| MT114 | M | 47 | IV | Thoracic wall | M1c | RT + IFN-α | − | Deceased | 10.7 |
| MT115 | F | 46 | IB | Left shoulder | NA | None | + | Stable | 11.4 |
| MT118 | F | 40 | IV | Left shoulder | M1a | ND | + | Progressor | 11.2 |
| MT120 | M | 36 | IV | Dorsal | M1b | DTIC | + | Progressor | 10.9 |
| MT122 | M | 23 | IIIC | Left leg | ND | None | + | Stable | 10.1 |
| MT123 | M | 43 | IV | Left flank | M1c | RT | − | Deceased | 10.1 |
| MT125 | F | 54 | IIIC | Right leg | N3 | None | + | Progressor | 7.6 |
| MT126 | F | 39 | IB | Left axillary | NA | None | + | Stable | 7.2 |
| MT127 | F | 37 | IV | Left foot | M1b | None | + | Progressor | 7.2 |
| MT128 | F | 34 | IIIB | Right shoulder | N2c | RT | + | Stable | 6.5 |
Immunologic response to therapy and post-vaccine survival
M male, F female, AJCC American Joint Committee on Cancer, ND not determinate, NA not applicable, CTX cyclophosphamide, DTIC dacarbazine, RT radiotherapy, TAM tamoxifen. Bold font = patients included in T cell population analysis